title: [99mTc-OCTREOTIDE in patients with neuroendocrine tumors from the GI tract].
abstract: BACKGROUND
  It has been demonstrated that scintigraphy with somatostatin analogues is useful for the diagnosis, staging and follow up of patients with neuroendocrine tumors from the gastrointestinal tract (NET-GIT). Some studies suggest that the use of 99mTc-Hydrazinonicotinyl-Tyr3-octreotide (99mTc-HYNIC-TOC) yields similar diagnostic results than the use of 111In-DTPA-octreotide.
  
  
  OBJECTIVE
  To determine the clinical value of scintigraphy using 99mTc-HYNIC-TOC for the detection of primary and secondary lesions in patients with NET-GIT.
  
  
  METHODS
  From September 2004 to May 2009, 32 patients (17 women, age range 18 to 82 years old) with histologically proven or clinically suspected NET-GIT underwent scintigraphy using 99mTc-HYNIC-TOC Patients underwent a whole body scan, with additional static images of abdomen and pelvis, followed by SPECT at 4-hrs post injection of 925 MBq of the tracer. Patients underwent clinical, imaging and histopathology follow-up during 3 to 18 months.
  
  
  RESULTS
  Histopathology demonstrated carcinoid tumor in 20 patients, insulinoma in 2, gastrinoma in 2 and non-specific NET-GIT in 6. Total sensitivity, specificity, positive predictive value, negative predictive value and accuracy were 87%, 100%, 100%, 89% and 94%, respectively. To detect the primary lesion, the values were 94%, 100% 100%, 94% and 97%, respectively and to detect secondary lesions, 79%, 100%, 100%, 86% and 91%, respectively.
  
  
  CONCLUSIONS
  99mTc-HYNIC-TOC is a specific somatostatin analog, with high affinity to receptor subtype SST-2, widely available and affordable by Latin American countries. It has a good performance to be used for diagnosis, staging and follow-up of patients with NET-GIT.
authors.affiliation: Consultorio de Medicina Nuclear Ferrari-Ferrando-Páez, Montevideo, Uruguay. gomezmilagros@yahoo.com.mx
authors.forename: Milagros
authors.initials: M
authors.lastname: Gómez
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Ferrando
authors.forename: Javier
authors.initials: J
authors.lastname: Vilar
authors.forename: Renzo
authors.initials: R
authors.lastname: Hitateguy
authors.forename: Belkis
authors.initials: B
authors.lastname: López
authors.forename: Ernesto
authors.initials: E
authors.lastname: Moreira
authors.forename: Miguel
authors.initials: M
authors.lastname: Kapitán
authors.forename: Fabio
authors.initials: F
authors.lastname: De Lima
authors.forename: Belkis
authors.initials: B
authors.lastname: Agüero
authors.forename: María
authors.initials: M
authors.lastname: Gabriela Villegas
authors.forename: Nelson
authors.initials: N
authors.lastname: Urdaneta
authors.forename: Enrique
authors.initials: E
authors.lastname: Gutiérrez
authors.forename: Alejandro
authors.initials: A
authors.lastname: Battegazzore
authors.forename: Karina
authors.initials: K
authors.lastname: Bayardo
authors.forename: Andrés
authors.initials: A
authors.lastname: Silveira
authors.forename: Graciela
authors.initials: G
authors.lastname: Lago
authors.forename: Antonio
authors.initials: A
authors.lastname: Páez
mesh_terms: D000293:Adolescent; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging*; D015282:Octreotide / Q000031:analogs & derivatives*; D015609:Organotechnetium Compounds; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging*; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D015899:Tomography, Emission-Computed, Single-Photon; D055815:Young Adult
chemical_list: C493098:99mTc-octreotide; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D015282:Octreotide